Mozart Therapeutics Announces Oral Presentation on MTX-101 at the American Diabetes Association 84th Scientific Session 2024

Data highlights potential of first-in-class CD8 Treg modulator

Ongoing Phase 1 clinical trial to evaluate MTX-101 in healthy adults and patients with celiac disease or type 1 diabetes

SEATTLE, June 21, 2024 /PRNewswire/ — Mozart Therapeutics, a clinical-stage biopharmaceutical company focused on developing CD8 Treg modulators for the treatment of autoimmune diseases, today presented new preclinical data on the company’s lead MTX program -101. The data was reviewed in an oral presentation at the American Diabetes Association 202484.^th Scientific sessions, held from June 21 to 24 at Orlando, Florida.

Courtney Crane, Ph.D., senior vice president of research at Mozart Therapeutics, presented data supporting the relevance of therapeutic modulation of the regulatory CD8 T cell network in autoimmune diseases, including type 1 diabetes (T1D). ). Additionally, data from in vitro studies using T1D-derived PBMCs demonstrate that MTX-101 treatment increases CD8 Treg prevalence and that CD8 Treg functionality (i.e., activation and cytolytic capacity) can be restored in this autoimmune context.

“We are pleased to highlight these new preclinical data on MTX-101 in type 1 diabetes,” said Dr. Crane. “These data support the ability of MTX-101 to restore CD8 Treg function in autoimmune diseases. We look forward to evaluating this candidate in patients with type 1 diabetes mellitus during Part B of our ongoing Phase 1 study.”

About the MTX-101

MTX-101 is a bispecific antibody targeting the inhibitory KIR and CD8 expressed on regulatory CD8 T cells. This autoimmune checkpoint inhibitor aims to restore the intrinsic functions of regulatory CD8 T cells, acting early in the autoimmune disease process to suppress and eliminate pathogenic cells, stop downstream inflammation and prevent the tissue destruction.

MTX-101 is currently being evaluated in a randomized, blinded, placebo-controlled Phase 1 clinical study (NCT06324604) in healthy adults (part A study) and in patients with celiac disease or type 1 diabetes mellitus (study part B).

About Therapeutic Mozart

Mozart Therapeutics is focused on developing first-in-class disease-modifying therapies for autoimmune diseases, using a novel approach to restore immune system function by targeting the CD8 T regulatory network. The company is headquartered in Seattle, WA. For more information, visit www.mozart-tx.com and follow the company on LinkedIn @Mozart–tx.com

SOURCE Therapeutic Mozart